Ranbaxy Receives Tentative Approval From Us FDA To Market Risperidone Oral Solution

... Ranbaxy Laboratories Limited (RLL) announced today that the Company has received tentative approval from the U.S. Food and Drug Administration (US FDA) to manufacture and market Risperidone Oral Solution, 1 mg/mL. Risperdal® (risperidone) is indicated for the treatment of schizophrenia. Total annual market sales for risperidone oral solution were $66 million (IMS - MAT: March 2006). [click link for full article] ...